




PHARMACEUTICAL 2018

Cell Source Inc.
Rank 326 of 342





PHARMACEUTICAL 2018

Cell Source Inc.
Rank 326 of 342

The relative strengths and weaknesses of Cell Source Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cell Source Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 135% points. The greatest weakness of Cell Source Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 205% points.

The company's Economic Capital Ratio, given in the ranking table, is -389%, being 434% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	532
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,089
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	840
Other Liabilities	0
Other Net Income	-790
Other Revenues	0
Property and Equipment	0
Research and Development	637
Selling, General and Administrative Expense	816

Output Variable	Value in 1000 USD
Assets	532
Liabilities	5,089
Expenses	2,293
Revenues	0
Stockholders Equity	-4,557
Net Income	-3,083
Comprehensive Net Income	-3,083
Economic Capital Ratio	-389%